NEWSROOM
Press Releases by Agendia
News
Press Releases
Agendia Research Shows Highest Risk MammaPrintยฎ Category Predicts Strongest Chemosensitivity in Women with Early-Stage HR+HER2- Breast Cancer
At the 2023 ASCO Annual Meeting, Agendia, Inc., a gene expression profiling company advancing personalized early-stage breast cancer care, will present data that proves MammaPrint can predict chemotherapy sensitivity in women with early-stage, HR+HER- breast cancer.
Read MoreAgendia Announces First Patient Enrolled in PROOFS Registry Trial to Determine Optimal Treatment and Ability to Forgo Chemotherapy for Premenopausal Women with Early HR+ Breast Cancer
Agendia partners with the West German Study Group to determine the benefit of ovarian function suppression, potentially reducing overtreatment with chemotherapy Trial reinforces Agendiaโs progress in developing practice-changing evidence to improve personalized cancer care Read More
Updated NCCNยฎ Guidelines Recognize MammaPrintยฎ UltraLow Risk Result, Highlighting its Clinical Utility for Women with Early-Stage Breast Cancer Who Can Safely Forgo Toxic Treatments with Excellent Survival Rates
Includes level one evidence that MammaPrint can help prevent unnecessary chemotherapyยน and endocrine therapyยฒ Con๏ฌrms Agendiaโs unique ability to identify tumors that have a very low risk of distant metastasis which can have implications for Read More
Agendia Level 1B Evidence Shows MammaPrint is the First and Only FDA-cleared Gene Expression Profiling Test to Predict Benefit from Extended Endocrine Therapy in Early-Stage Breast Cancer Patients
Late-breaking abstract at the 2022 San Antonio Breast Cancer Symposium (SABCS) will illustrate MammaPrintโs ability to identify strongest candidates for extended endocrine therapy among HR+HER2- post-menopausal women December 08, 2022 09:00 AM Eastern Standard Time Read More
Level One Evidence Proves Premenopausal Patients within the Ultra-Low Subset of Agendiaโs MammaPrint Low Risk Result Can Safely Forgo Chemotherapy
MammaPrint is the only FDA-cleared gene expression test to identify early breast cancer tumors with an Ultra-Low risk that can safely avoid chemotherapy, with a 99% breast cancer specific survival (BCSS) and 97% distant metastasis Read More
Agendia Spotlights the Future of Personalized Breast Cancer Care at 2022 San Antonio Breast Cancer Symposium
Demonstrates the ongoing impact of its 10,000-patient FLEX trial to fuel breast cancer research and produce practice-changing results All six presentations will emphasize how MammaPrintยฎ and BluePrintยฎ empower personalized, proactive treatment decisions with test results Read More
Agendia Announces First Patient Enrolled in Prospective LESS Clinical Study, Sponsored by Unicancer, to De-escalate Endocrine Therapy in Women with Early Breast Cancer
The LESS study will evaluate reduced endocrine therapy for HR+/HER2- patients with MammaPrintยฎ Ultra Low tumors to improve quality of life without compromising outcomes Study strengthens Agendiaโs growing global footprint in breast cancer to inform Read More
